Investec has advised Aliance Pharma Plc ('Alliance Pharma') on a £34m fundraising, the proceeds of which will be used to part-fund the £60m acquisition of the rights to Nizoral in the APAC region from Johnson & Johnson.
Founded in 1996, Alliance Pharma owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company outsources capital-intensive activities such as manufacturing, warehousing and logistics to specialist providers, and focuses on marketing and all the associated business and regulatory activities. The Company is listed on AIM with a market capitalisation of £500m.
Investec acted as joint bookrunner, joint underwriter and joint broker to Alliance Pharma Plc in relation to the fundraising, generating considerable demand from new as well as existing
The acquisition boosts Alliance Pharma's exposure to fast-growing APAC markets and is expected to generate material earnings enhancement in the first full year of ownership.